berberine has been researched along with framycetin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Herdewijn, P; Maiti, M; Nauwelaerts, K | 1 |
| Angra, SK; Mahajan, VM; Mohan, M; Pant, CR | 1 |
| Chen, M; Li, H; Li, Z; Lou, X; Ma, S; Shen, R; Song, J; Zhang, J | 1 |
1 trial(s) available for berberine and framycetin
| Article | Year |
|---|---|
Berberine in trachoma. (A clinical trial).
Topics: Berberine; Berberine Alkaloids; Child; Clinical Trials as Topic; Double-Blind Method; Humans; Neomycin; Sulfacetamide; Trachoma | 1982 |
2 other study(ies) available for berberine and framycetin
| Article | Year |
|---|---|
Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
Topics: Aminoglycosides; Antineoplastic Agents; Base Sequence; DEAD-box RNA Helicases; Humans; MicroRNAs; Models, Biological; Molecular Sequence Data; Ribonuclease III; RNA Processing, Post-Transcriptional | 2012 |
Berberine protects against neomycin-induced ototoxicity by reducing ROS generation and activating the PI3K/AKT pathway.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Berberine; Hearing Loss; Mice; Neomycin; Ototoxicity; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2023 |